secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-067231
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics appoints Lee Anderson as Chief Commercial Officer; 30-year diagnostics veteran to lead PreTRM rollout
--------------------------------------------------------------------------------

- Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.
- Anderson previously led US Oncology Sales at Genomic Health (acquired by Exact Sciences) and was CCO at Biofidelity.
- He will drive commercial adoption of the PreTRM test following positive PRIME study results.
- Company is in commercial phase; Anderson brings over 30 years of healthcare sales and marketing leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000095017025067231/0000950170-25-067231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000095017025067231/sera-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer